These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22350134)

  • 1. Cystatin C is not a good candidate biomarker for HNF1A-MODY.
    Nowak N; Szopa M; Thanabalasingham G; McDonald TJ; Colclough K; Skupien J; James TJ; Kiec-Wilk B; Kozek E; Mlynarski W; Hattersley AT; Owen KR; Malecki MT
    Acta Diabetol; 2013 Oct; 50(5):815-20. PubMed ID: 22350134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Glomerular Filtration Rate Estimation from Serum Creatinine and Cystatin C in HNF1A-MODY and Other Types of Diabetes.
    Szopa M; Kapusta M; Matejko B; Klupa T; Koblik T; Kiec-Wilk B; Borowiec M; Malecki MT
    J Diabetes Res; 2015; 2015():183094. PubMed ID: 26347889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
    Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
    Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
    Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
    Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
    Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
    Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
    Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in HNF1A result in marked alterations of plasma glycan profile.
    Thanabalasingham G; Huffman JE; Kattla JJ; Novokmet M; Rudan I; Gloyn AL; Hayward C; Adamczyk B; Reynolds RM; Muzinic A; Hassanali N; Pucic M; Bennett AJ; Essafi A; Polasek O; Mughal SA; Redzic I; Primorac D; Zgaga L; Kolcic I; Hansen T; Gasperikova D; Tjora E; Strachan MW; Nielsen T; Stanik J; Klimes I; Pedersen OB; Njølstad PR; Wild SH; Gyllensten U; Gornik O; Wilson JF; Hastie ND; Campbell H; McCarthy MI; Rudd PM; Owen KR; Lauc G; Wright AF
    Diabetes; 2013 Apr; 62(4):1329-37. PubMed ID: 23274891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of creatinine-based and cystatin C-based equations for estimation of glomerular filtration rate in type 1 diabetic patients.
    Domingueti CP; Fóscolo RB; Simões E Silva AC; Dusse LM; Reis JS; Carvalho Md; Fernandes AP; Gomes KB
    Arch Endocrinol Metab; 2016 Apr; 60(2):108-16. PubMed ID: 27191046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
    Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
    Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?
    Karlsson E; Shaat N; Groop L
    Diabet Med; 2008 Jul; 25(7):788-91. PubMed ID: 18513302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
    Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
    Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
    Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maturity onset diabetes of the young due to
    Pavić T; Juszczak A; Pape Medvidović E; Burrows C; Šekerija M; Bennett AJ; Ćuća Knežević J; Gloyn AL; Lauc G; McCarthy MI; Gornik O; Owen KR
    Biochem Med (Zagreb); 2018 Jun; 28(2):020703. PubMed ID: 29666556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HNF1A gene p.I27L is associated with early-onset, maturity-onset diabetes of the young-like diabetes in Turkey.
    Beysel S; Eyerci N; Pinarli FA; Kizilgul M; Ozcelik O; Caliskan M; Cakal E
    BMC Endocr Disord; 2019 May; 19(1):51. PubMed ID: 31109344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
    Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
    Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes.
    McDonald TJ; McEneny J; Pearson ER; Thanabalasingham G; Szopa M; Shields BM; Ellard S; Owen KR; Malecki MT; Hattersley AT; Young IS
    Clin Chim Acta; 2012 May; 413(9-10):927-32. PubMed ID: 22360925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
    Urbanova J; Andel M; Potockova J; Klima J; Macek J; Ptacek P; Mat'oska V; Kumstyrova T; Heneberg P
    Curr Pharm Des; 2015; 21(39):5736-48. PubMed ID: 26446475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.